Haemophilia A in two premature infants.
The incidence of prematurity in Germany is about 10% and premature infants with haemophilia A (OMIM 306700) are in fact very rare. We report two new cases, one born in the 28th gestational week, weighing 1200 g with a factor VIII (FVIII) level of 0.03 IU/ml treated with bolus injections of plasma derived FVIII concentrate (pdFVIII), and one born at week 30, weighing only 710 g with a factor level of <0.01 IU/ml and treated with recombinant FVIII concentrate (rFVIII). Recovery of FVIII was 96% in case 1 and 120% in case 2, FVIII half-life was 6 h and 8 h, respectively. During FVIII substitution, neither bleeding, thrombosis nor inhibitor development were noted in both infants.


CONCLUSIONS
Immediate and frequent factor VIII substitution appears to be safe and effective for prophylaxis and treatment in premature haemophilic neonates.
Bidlingmaier
Christoph
C
Department of Paediatric Haemostaseology, Dr. von Hauner's Children's Hospital, University of Munich, Lindwurmstrasse 4, 80337 Munich, Germany. christoph.bidlingmaier@med.uni-muenchen.de
Bergmann
Frauke
F
Kurnik
Karin
K
D004334:Drug Administration Schedule; D005169:Factor VIII / Q000032:analysis / Q000627:therapeutic use*; D006207:Half-Life; D006467:Hemophilia A / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D005169:Factor VIII